EIP
CRSP icon

Ellis Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Ellis Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$16K – 782
2021
Q2 		$16K Hold
100
– – ﹤0.01% 542
2021
Q1 		$12K Buy
+100
New +$15.1K ﹤0.01% 556

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Ellis Investment Partners's CRSP Position: Q3 2021 in Review

Ellis Investment Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 100 shares — an estimated $16K sold.

Ellis Investment Partners first reported a position in CRSP in Q1 2021 and held it in 2 quarters. The position peaked at $16K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Ellis Investment Partners reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ellis Investment Partners sold 100 CRISPR Therapeutics shares in Q3 2021, an estimated $16K.
  • Ellis Investment Partners first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 2 quarters.
  • Ellis Investment Partners's CRISPR Therapeutics position peaked at $16K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Ellis Investment Partners's 13F filing for Q3 2021, filed 21 Oct 2021.